Therapeutic potential of human minor salivary gland epithelial progenitor cells in liver regeneration

Chen Zhang, Yan Li, Xiang-yu Zhang, Lei Liu, Hai-zhou Tong, Ting-Lu Han, Wan-di Li, Xiao-lei Jin, Ning-bei Yin, Tao Song, Hai-dong Li, Juan Zhi, Zhen-min Zhao & Lin Lu

Liver disease is a serious problem affecting millions of people with continually increasing prevalence. Stem cell therapy has become a promising treatment for liver dysfunction. We previously reported on human minor salivary gland mesenchymal stem cells (hMSGMSCs), which are highly self-renewable with multi-potent differentiation capability. In this study, keratinocyte-like cells with self-regeneration and hepatic differentiation potential were isolated and characterized, and named human minor salivary gland epithelial progenitor cells (hMSG-EpiPCs). hMSG-EpiPCs were easily obtained via minor intraoral incision; they expressed epithelial progenitor/stem cell and other tissue stem cell markers such as CD29, CD49f, cytokeratins, ABCG2, PLET-1, salivary epithelial cell markers CD44 and CD166, and the Wnt target related gene LGR5 and LGR6. The cells were induced into functional hepatocytes in vitro which expressed liver-associated markers ALB, CYP3A4, AAT, and CK18. Upon transplantation in vivo, they ameliorated severe acute liver damage in SCID mice caused by carbon tetrachloride (CCL4) injection. In a two-thirds partial hepatectomy mouse model, the transplanted cells survived at least 4 weeks and exhibited hepatic potential. These findings demonstrate that hMSG-EpiPCs have potential as a cellular therapy basis for hepatic diseases, physiological and toxicology studies and regenerative medicine.
Major salivary gland-derived epithelial cells are well-studied\textsuperscript{11,16–21} and have been successfully differentiated into both salivary gland and endodermal cell lineages, such as hepatocytes and pancreatic beta cells\textsuperscript{11,22,23}. However, the major salivary glands do not seem to be an ideal and safe option for stem/progenitor cell harvest because of the invasive procedure to the donor site, whereas the minor salivary glands located in oral mucosa appear to be an optimal source with easy access and less invasion\textsuperscript{24}. Therefore, we hypothesized that the minor salivary glands might contain epithelial stem/progenitor cells with ability to differentiate into other endodermal lineages. Previously, we reported the existence of both human minor salivary gland mesenchymal stem cells (hMSGMSCs) and epithelial progenitor cells (hMSG-EpiPCs) derived from human labial salivary glands\textsuperscript{25,26}. This present study further details the phenotypes and characterization of the epithelial progenitor cells.

**Results**

**Isolation and self-renewal capacity of hMSG-EpiPCs.** Tissue explant method was used for primary cell culture after human minor salivary glands (hMSG) were surgically harvested. After 5–10 days of culture, keratinocyte-like cells migrated from the tissue explants (Fig. 1a). The first passage usually occurred at day 7–10, when the cells around the tissue explant reached 80%–90% confluence. Normally, we obtained approximately $5 \times 10^6$ homogeneously shaped cells at passage 3 (Fig. 1b). During the passaging, the cell growth and morphology did not show obvious changes until 25 passages (Fig. 1c). MTT and colony formation assays were performed for the cells at passage 5 to test their proliferation ability. The cell population doubling time was 70.85 hours on average, whereas the efficiency of colony formation was 12.3% ± 2.1%. Such results suggest the existence of a population of epithelial progenitor cells derived from hMSGs that could maintain high proliferation capacity during culture in vitro; we named the population as human minor salivary gland epithelial progenitor cells (hMSG-EpiPCs).

**Identification and characterization of hMSG-EpiPCs.** Flow cytometry analysis of these keratinocyte-like cells at passage 5 demonstrated that the expanded cells highly expressed the epithelial lineage-related markers CD29, CD49f, and CK-KIT (CK14, CK15, CK16, and CK19) as well as the salivary epithelial cell markers CD44 and CD166 (Table 1, Supplementary Fig. S1a). In addition, the cells were negative for the mesenchymal stem cell markers CD90, CD105, CD106, and STRO-1, indicating non-mesenchymal origin. Interestingly, in contrast to other epithelial stem/progenitor cells, these cells included a population positive for the hESC marker SOX2, suggesting consistency with other stem cell types.

The phenotypes of both hMSG-EpiPCs and hMSG tissues were determined via immunofluorescence staining (Fig. 1d and e). Positive expression of the epithelial lineage-related markers CK15, CK19, ABCG2, and PLET-1 was observed. We also detected human telomerase reverse transcriptase (hTERT), the thymic epithelial progenitor cell markers K5 and K8, the endothelial cell marker CD31, and the basal lamina protein laminin in hMSG-EpiPCs and minor salivary gland tissues. Furthermore, the Wnt pathway target genes LGR5 and LGR6, markers of several lineages of stem/progenitor cells, including liver-derived stem cells, were also expressed. Tissue immunofluorescent staining showed expression of the epithelial lineage-related markers CK18, CK19, K5, and K8 and the Wnt target gene related LGR5 in the excretory duct and acinus; CK15-positive and LGR6-positive cells were located only in the excretory duct, indicating that these cells originated from the excretory duct of the hMSG.

These results demonstrate that hMSG-EpiPCs expressed phenotypes of epithelial stem/progenitor cells and other adult stem cell types, and suggest that these cells originated from the excretory duct part of the minor salivary glands.

**Hepatic induction of hMSG-EpiPCs in vitro.** To induce hepatic differentiation of hMSG-EpiPCs in vitro, cells were cultured in 24-well plates containing thick Matrigel with conditioned medium for 16 days. hMSG-EpiPCs formed spheres in Matrigel during the induction procedure (Fig. 2a). After induction, the cells expressed a diverse panel of markers for hepatocytes including ALB, CYP3A4, and CK18 while the uninduced cells were negative (Fig. 2d). Gene expression analysis showed that expression of the hepatocellular markers ALB, CYP3A4, CK18, and AAT increased during differentiation (Fig. 2f). CYP450 activity, indocyanine green (ICG) uptake, and periodic acid–Schiff staining tests were performed to further validate function of the induced hepatocytes(Fig. 2b, c, and e). The results suggested that successful hepatic differentiation was achieved in vitro, indicating the hepatic differentiation potential of hMSG-EpiPCs.

**Therapeutic potential of hMSG-EpiPCs in CCl$_4$-induced acute fulminant liver failure.** To test whether hMSG-EpiPCs could promote liver regeneration in vivo, we performed cell transplantation in the animal model of fulminant hepatic injury. By injection of CCl$_4$ acute liver injury was triggered in severe combined immunodeficient (SCID) mice. The cell-treated group was transplanted with hMSG-EpiPCs, whereas the sham group was treated with PBS, and no disease model or treatment was applied in the control group. Starting at day 1 after CCl$_4$ injection, the body weight (BW) of the mice in the sham group kept decreasing until day 5 as a result of inflammatory hepatomegaly. Three mice (30% mortality) died 2 days after CCl$_4$ injection. While all mice treated with hMSG-EpiPCs survived and recovered from liver damage in a shorter time period, along with a lower ratio of liver weight to BW (Fig. 3a and b).

Human serum albumin (HSA) was detected in the serum of treated mice 2 weeks after injection of the cells (Fig. 3c), whereas it was scarcely detected in the sham group. In addition, in both disease model groups, a dramatic increase in serum alanine transaminase (ALT), aspartate transaminase (AST), and total bilirubin (TBIL) was detected 2 days after CCl$_4$ injection (1 day after hMSG-EpiPC/PBS treatment), indicating severe acute liver damage. ALT, AST, and TBIL levels of animals in the experimental-group decreased to baseline significantly faster than the levels in the sham group (Fig. 3d).
Histological analysis revealed that hepatocyte necrosis occurred 2 days after injection of CCl$_4$ in both hMSG-EpiPC- and PBS-treated groups (24 h after hMSG-EpiPC or PBS injection) (Fig. 4a). Hepatocytes presented as vacuolar, hydropic, karyorrhexic, and karyolytic, and erythrocyte diapedesis was also observed. At 8 days post CCl$_4$ injection (7 days post hMSG-EpiPC or PBS injection), both groups had recovered from acute liver damage, but diseased hepatocytes still could be observed in the PBS-treated group while no such cells existed in the hMSG-EpiPC-treated group, suggesting enhanced liver regeneration in the hMSG-EpiPC-treated mice.

**Figure 1.** Culture and Characterization of hMSG-EpiPCs. (a) Primary culture for hMSG-EpiPCs at day 5. (b) Expanded hMSG-EpiPCs of passage 3. (c) Expanded hMSG-EpiPCs of passage 25. (d) Immunostaining of expanded hMSG-EpiPCs of passage 5. (e) Immunostaining of hMSG tissues (Yellow arrows: excretory duct, white arrows: acinus).
To test the survival of the cells, we transplanted hMSG-EpiSCs labelled by cell-tracker CM-Dil (Supplementary Fig. S1b) to this mouse model. Liver tissues were harvested two weeks after the transplantation. Immunofluorescence assays showed that several CM-Dil-positive cells survived in vivo and expressed for AFP, ALB and CK18 (Supplementary Fig. S1c).

Therapeutic potential of hMSG-EpiPCs in a mouse model of partial hepatectomy. To in detail validate the survival of hMSG-EpiPCs in vivo, we further transplanted hMSG-EpiSCs labelled with cell-tracker CM-Dil in a mouse model of two-thirds partial hepatectomy. We euthanized cell-treated mice every week post transplantation and harvested the liver tissues for immunofluorescence assays (Fig. 4b) and the liver tissues of normal SCID mice were stained as control (Fig. S1d). One week post injection, few CM-Dil-positive cells were positive for ALB, AFP, CYP3A4, CK18, or CK19. More CM-Dil-positive cells expressed ALB, AFP, CYP3A4, or CK18 two weeks after injection. Cells double-positive for CK19 and CM-Dil appeared surrounding the portal tract. At 3 weeks after transplantation, ALB-positive cells formed cluster involving several CM-Dil-labelled cells. Count of AFP-positive cells decreased. More CM-Dil-labelled cells occurred around the portal tract, and some of them were also positive for CK19, indicating participation of the transplanted hMSG-EpiPCs in the reconstruction of the intrahepatic bile duct. CYP3A4 and CK18 were strongly expressed at this time, with many of the positive cells double-positive with CM-Dil. At 4 weeks after transplantation, few AFP-positive cells showed double positivity. We found abundant CYP3A4/CM-Dil, ALB/CM-Dil and CK18/CM-Dil co-positive cells, as well as CK19/CM-Dil co-positive cells surrounding the portal tract (Table 2). No evidence of hepatic tumour formation in the hMSG-EpiPC-treated livers was found at any time point.

**Discussion**

The lack of an easily accessed population of human adult endodermal stem/progenitor cells with multi-differentiation potential is a challenge for cell therapy and regenerative medicine. The hMSGs locating in the oral mucosa may be promising candidates as cell source for their easy accessibility and adequate cell quantity. In a previous study, we reported the existence of hMSGMSCs with phenotypes of embryonic and mesenchymal stem cells. These hMSGMSCs are highly self-renewable and have multi-potent differentiation potential. The hMSG-EpiPCs we reported here were also isolated from primary cultured hMSG. However, these keratinocyte-like hMSG-EpiPCs showed a different shape and phenotype that suggested an epithelial lineage. These hMSG-EpiSCs showed high efficiency in endodermal differentiation in vitro, which inspired us to further research their therapeutic potential in liver regeneration.

In the current study, cells expressing CK18, CK19, K5, K8, and/or LGR5 were found in both the excretory duct and acinus, whereas expression of CK15 and LGR6 was observed only in the excretory duct. Thus, we propose the existence of an epithelial progenitor cell population mainly derived from the hMSG excretory duct; these oval-shaped keratinocyte-like cells were named hMSG-EpiPCs.

In contrast to mesenchymal stem cells, there are no universal standard phenotypic markers for stem/progenitor cells of epithelial lineage. Various markers are used to mark epithelial stem/progenitor cells with various origins. Flow cytometry analysis detected high expression of the epithelial lineage-related markers CD29, CD49f, CK-KIT, CD90, CD105, CD106, STRO-1, CD44, CD166, SOX2, SSEA-1, NANOG, OCT4, ALB, CD117, and other markers (Table 1). Averaged percentage of flow cytometry analysis of hMSG-EpiPCs at passage 5 for the cell markers are shown in the table. Standard deviation is shown as s.d.

|                      | Average | s.d. |
|----------------------|---------|------|
| **Epithelial lineage-related markers** |         |      |
| CD29                 | 99.23%  | 0.76%|
| CD49                 | 93.61%  | 6.07%|
| CK-KIT               | 95.03%  | 4.90%|
| **Salivary epithelial cell markers** |         |      |
| CD44                 | 83.07%  | 6.44%|
| CD166                | 99.83%  | 0.12%|
| **Mesenchymal stem cell markers** |         |      |
| CD90                 | 2.08%   | 1.36%|
| CD105                | 2.34%   | 0.37%|
| CD106                | 1.87%   | 0.86%|
| STRO-1               | 1.64%   | 0.84%|
| **Hematopoietic lineage-related markers** |         |      |
| CD117                | 0.44%   | 0.45%|
| **Embryonic stem cell markers** |         |      |
| SOX2                 | 67.03%  | 4.67%|
| SSEA-1               | 5.13%   | 1.73%|
| NANOG                | 1.11%   | 0.86%|
| OCT4                 | 1.99%   | 1.28%|
| **Other markers**    |         |      |
| ALB                  | 0.58%   | 0.22%|

Table 1. Flow cytometry analysis of hMSG-EpiPCs. Averaged percentage of flow cytometry analysis of hMSG-EpiPCs at passage 5 for the cell markers are shown in the table. Standard deviation is shown as s.d.
CD49f, and CK-KIT in hMSG-EpiPCs, together with markers previously identified in salivary-related cells such as CD44 and CD166. ABCG2, which has been reported to be positively expressed in progenitor cells isolated from mouse submandibular glands, was also found to be expressed in epithelial progenitor cells isolated from mouse submandibular glands.

Figure 2. Hepatic differentiation of hMSG-EpiPCs in vitro. (a) Picture of induced hMSG-EpiPCs taken on day 4, 8, 12 and 16 from left to right. (b) Indocyanine green (ICG) uptake assay on day 16 of hepatic induction and the control group. (c) Periodic acid-Schiff (PAS) staining on day 16 of hepatic induction and the control group. (d) Immunostaining on day 16 of hepatic induced and uninduced cells for ALB, CK18 and CYP3A4 from left to right. (e) CYP450 activity analysis on day 16 of hepatic induction for CYP3A4 and CYP2C19. (f) Quantitative real-time PCR analysis of relative mRNA expression of hMSG-EpiPCs and induced hepatic cells on day 16. (***P < 0.01; n ≥ 3).
hMSGs. Immunofluorescence staining revealed that hMSG-EpiPCs expressed hTERT, which exerts control over cell proliferation. Additionally, the thymic epithelial progenitor cell markers K5, K8, and PLET-1 were expressed in hMSG-EpiPCs and in minor salivary gland tissue. Cytokeratins are proteins found in the intracytoplasmic...

Figure 3. hMSG-EpiPCs treatment promotes liver regeneration after acute injury. (a) Changes in body weight of CCl4-injected mice show that hMSG-EpiPCs treatment group restored body weight faster than control group. (b) The ratio of liver weight to body weight of the hMSG-EpiPCs treatment mice was lower than that of the PBS-treated mice. (c) HSA could be detected in hMSG-EpiPCs treatment group. (d) Serum ALT, AST and TBIL level increased in all mice 2 day after CCl4 injection, and decreased faster in hMSG-EpiPCs treatment group than that of control mice. (*P < 0.05; **P < 0.01, n ≥ 3).
cytoskeleton of epithelial tissue that were previously reported to identify mouse postnatal mammary gland epithelial cells, human hair follicle stem cells, and human liver progenitor cells. In addition, Lombaert IM previously reported that salivary gland cells isolated from murine submandibular glands were positive for CD117, while hMSG-EpiPCs were negative. These observations help to confirm the existence of hMSG-EpiPCs.

Figure 4. Hepatic differentiation of hMSG-EpiPCs in vivo. (a) H&E staining of mice liver section on day 1 and 7 post PBS and hMSG-EpiPCs injection (White arrows: erythrocyte diapedesis, yellow arrows: diseased hepatocytes). (b) Immunostaining 1, 2, 3 and 4 weeks after hMSG-EpiPCs transplantation from left to right, green fluorescence signal for AFP, ALB, CK18, CK19 and CYP3A4 from top to bottom, and red for CM-Dil labeling.
In addition to these epithelial-lineage markers, hMSG-EpiPCs were also positive for the endothelial cell marker CD31, which suggest their applicability to vascular tissue engineering. Expression of the basal lamina protein laminin was also observed. In rat salivary glands, ligation of main ducts caused the disappearance of acinar cells and proliferation of ductal cells around laminin+ cells, which suggests activation of tissue progenitor cells in a damaged state45. Cultured hMSG-EpiPCs included a population of cells positive for the hESC marker Sox2, which maintains pluripotency of hESCs and regulates formation of various epithelial tissues during foetal development37,38, which may explain the high proliferation ability of hMSG-EpiPCs.

Additionally, the Wnt target genes LGR5 and LGR6, which are markers of several stem/progenitor cells14,39–46, were also positively expressed, especially LGR5, which is a liver-derived stem cell marker13,35. This LGR5 expression supports the potential use of hMSG-EpiPCs as a cellular basis for regenerative liver medicine.

In the present study, the hepatic cells differentiated from hMSG-EpiSCs expressed ALB, CK18, and CYP3A4. The expression of ALB, CK18, and CYP3A4 demonstrated fully mature hepatocyte function. In addition, Q-PCR showed that expression of AAT increased during differentiation. AAT is mainly produced in the liver and protects the lungs against proteolytic damage47. However, expression of AAT was not observed on immunofluorescent staining, and this result thus needs further study. Cell functionality was validated through analyses of CYP450 activity, ICG uptake, and periodic acid-Schiff staining, indicating that fully functional hepatocytes were acquired from hMSG-EpiPCs.

To further test the clinical potential of hMSG-EpiPCs, we used different animal models to validate the therapy effect. CCl4 is a model substance for elucidating hepatotoxic mechanisms such as hepatocellular death, fibrosis, fatty degeneration, and carcinogenicity48. After injection of 20% CCl4, the levels of ALT, AST, and TBIL dramatically increased as a result of enzyme release caused by massive hepatocyte damage, indicating acute and massive death of hepatocytes, which also caused the body weight of the mice to decrease. Hepatomegaly occurred, according to the pathological sections. In the PBS-treated group, 3 mice (30% mortality) died 2 d after CCl4 injection. The ALT, AST, and TBIL levels decreased faster in the hMSG-EpiPC-treated mice than in their PBS-treated counterparts, along with faster body weight increases, faster hepatocyte regeneration, a higher survival rate, and lower ratio of liver weight to BW. Moreover, the detection of HSA in the serum of hMSG-EpiPC-treated mice and the immunofluorescence assays result two weeks after cell injection implied proliferation and hepatic differentiation of transplanted hMSG-EpiPCs. The mouse model of two-thirds partial hepatectomy is a relatively “clean” model of hepatic damage, with no massive hepatocyte death and mild inflammation; this model does not cause inflammatory cell infiltration or negatively impact the engraftment of transplanted stem/progenitor cells49. Weber et al. reported that after 70% hepatectomy, liver regeneration was activated immediately, and the weight of the remaining liver had increased to a normal level 20 d after the surgery50. Our result shows that after hMSG-EpiPC injection, the number of ALB/CM-Dil, CK18/CM-Dil and CYP3A4/CM-Dil double-positive cells increased daily, whereas AFP/CM-Dil double-positive cells occurred 1 week after transplantation, reached their highest level 2 weeks after transplantation, and then gradually decreased in number, which suggests both proliferation and hepatic differentiation of the transplanted hMSG-EpiPCs. Both differentiated and non-differentiated hMSG-EpiPCs expressed CK19 in vitro, which is a marker of both the minor salivary gland excretory duct and the bile duct. After injection of hMSG-EpiPCs, most of the CM-Dil-positive cells were negative for CK19; a few positive cells occurred only in the portal area. Therefore, we speculate that hMSG-EpiPCs promote liver regeneration through two major mechanisms. One is by differentiating into hepatocytes expressing ALB, AFP, CK18, and CYP3A4. The other is by migrating into the portal area and participating in the reconstruction of the intrahepatichileduct. Therefore, hMSG-EpiPCs showed a positive effect in both disease models, indicating that they are a promising candidate for treatment of liver diseases.

Conclusion
In the current study, we isolated and characterized a population of epithelial progenitor cells from hMSGs. These cells have self-renewal and hepatic differentiation capacity. We also demonstrated the ability of these cells to ameliorate liver damage through transplantation in acute liver injury models. These cells have potential for hepatic differentiation. Our study highlights the importance of hMSG-EpiPCs in hepatic disease modelling, physiological and toxicology studies, regenerative medicine, and clinical therapy.

Method
Ethical Statement. All experimental procedures were approved by Institutional Review Board of the Plastic Surgery Hospital, Peking Union Medical College and Animal Care and Use Committee of the Plastic Surgery Hospital, Peking Union Medical College, and were in accordance with the Declaration of Helsinki (2013). Tissues containing salivary glands were harvested from consenting donor patients with cleft lip and palate deformity.

Table 2. Immunofluorescence Analysis of hMSG-EpiPCs Transplantation in vivo. Averaged number of injected CM-Dil-labeled double positive cells in different time after the transplantation are shown in the table.

| Antibody | 1 Week | 2 Weeks | 3 Weeks | 4 Weeks |
|----------|--------|---------|---------|---------|
| AFP      | 16.4 ± 3.4 | 25.4 ± 4.5 | 13.6 ± 3.5 | 4.8 ± 4.1 |
| ALB      | 6.5 ± 2.9  | 12.8 ± 3.9 | 12.5 ± 4.7 | 13.5 ± 3.8 |
| CK18     | 5.0 ± 2.2  | 14.0 ± 4.2 | 20.5 ± 4.5 | 20 ± 3.8  |
| CK19     | 1.8 ± 0.8  | 2.8 ± 1.1  | 3.0 ± 1.3  | 2.5 ± 0.5  |
| CYP3A4   | 6.5 ± 2.9  | 20.8 ± 2.4 | 28.5 ± 4.1 | 27.3 ± 3.8 |
during surgery, and none of these patients was diagnosed with salivary gland diseases. All these patients have signed the Specimen Collection Informed Consent.

**Mice.** Female severe combined immune deficiency (SCID/Beige) mice aged 6–8 weeks were provided by the Academy of Military Medical Sciences (Beijing, China).

**Human Salivary Gland Tissue and Cell Culture.** Tissues specimens containing salivary glands were transported in 15-mm centrifuge tubes filled with regular medium (Dulbecco’s modified Eagles medium (DMEM, HyClone), supplemented with 1% penicillin and streptomycin (5,000 μg/mL (Sigma), 1% GlutaMAX supplement (Gibco), and 10% foetal bovine serum (Gibco)). When isolating hMSG-EpiPCs for primary culture, excess connective tissues were removed by scissors. The glands were cut into small pieces no larger than 1 mm³ and placed at the base of the culture flask and then incubated for 3 to 4 h, before 5 mL of keratinocyte medium (ScienceCell) was added.

The medium was first changed at day 5, and then changed every 3 days. Cells at 80% confluence were harvested with 0.25% trypsin and re-seeded in a cell culture dish. The media were changed every 3 days. Cells were passaged using 0.25% trypsin (HyClone) at 80% confluence in a 1:3 split ratio.

**MTT Assay.** The MTT assay (Sigma) was performed to determine the proliferation ability of the cells. At 80% confluence, cells at passage 5 were trypsinized and transferred to a 96-well plate at a density of 2 × 10³ per well. MTT solution was added to each well of the 96-well culture plate, which was then incubated at 37 °C for 4 h. After the MTT solution was removed, samples were dissolved in DMSO (Sigma) and transferred to new 96-well plates. The absorbance of each well was measured at a wavelength of 490 nm for 7 continuous days. The cell population doubling time was calculated as previously described.

**Cell Colony Formation Assay.** Cells at passage 5 were trypsinized and seeded in a 60-mm dish at density of 200 cells and then cultured for 2 weeks. The media were changed every 3 days. The surviving colonies (>50 cells/colony) were counted using crystal violet staining.

**Flow Cytometry.** Samples at passage 5 were collected from 60-mm dishes at 80% confluence (1 × 10⁶ cells). The cells were washed, fixed and incubated with antibodies as previously described. We used a FACSaria II system (BD) for analyses. For each marker, 3 independent biological experiments were performed. FlowJo 7.6.1 software (Tree Star Inc. OR) was used to analyse the acquired data.

**Hepatic Differentiation.** We used a thick Matrigel culture method to induce hepatocytes according to the manufacturer’s instructions (BD). Cells at passage 4 and 80% confluence were trypsinized and counted. Then, 1 × 10⁴ cells were resuspended in liver induction medium, added to 24-well plates/chambers, and further cultured under 5% CO₂ at 37 °C in a cell incubator. The liver induction medium was changed every 3 days for a period of 16 days. It consisted of KM basal medium (ScienceCell) supplemented with 1% ITS Liquid Media Supplement (Sigma), 10 ng/mL IGF (Peprotech), 20 ng/mL EGF (Peprotech), 50 μg/mL BPE (ScienceCell), 20 ng/mL HGF (Peprotech), 10 mM nicotinamide (Sigma), 100 mM dexamethasone (Sigma), and 100 μg/mL penicillin-streptomycin (Sigma).

**Transplantation Assay.** To determine whether transplanted MSG-hEpiPCs could promote liver regeneration in vivo, liver damage was produced in the mice by intraperitoneal injection of 10 ml/kg CCl₄ dissolved in olive oil (1:4). At 24 h after injection, 150 μL suspensions of hMSG-EpiPCs at passage 5 labeled with CM-Dil were injected via the caudal vein (approximately including 2 × 10⁶ cells). The body weight of each mouse was measured, and liver tissue and serum were collected 1 day, 3 days, 1 week, and 2 weeks after hMSG-EpiPC injection for assays.

To test the proliferation of transplanted hMSG-EpiPCs in vivo, a mouse model of two-thirds partial hepatectomy was established as previously described, after which hMSG-EpiPCs at passage 5 were labelled with CM-Dil and injected immediately as described above. The liver tissues were collected at 1 week, 2 weeks, 3 weeks, and 1 month after hMSG-EpiPC injection for immunofluorescence staining. The quantity of CM-Dil-labeled double positive cells in the immunofluorescence staining sections was measured under a Nikon TE2000-S microscope. Three researchers blinded to the groups counted the number in 15 randomized fields on each section in 40 × magnification.

**Immunohistochemistry and Immunofluorescence.** Slides of hMSGs, cells, and liver tissues were fixed for 15 min in precooled 4% paraformaldehyde. The hMSG sections were stained with hematoxylin and eosin. For immunofluorescence, slides of tissues and cells were stained using standard techniques as described previously. Images were acquired using a Nikon TE2000-S microscope, and an Olympus laser scanning confocal microscope.

**Quantitative Reverse Transcriptase–polymerase Chain Reaction.** Total RNA was obtained from cultured cells using the RNeasy Mini kit (Qiagen) and reverse-transcribed using M-MLV (Invitrogen) according to the manufacturer’s protocol. Real-time PCR was performed using SYBR Green I Master (Roche) on a LightCycler 480 system (Roche Molecular Systems, CA). Expression levels of desired genes were normalized to those of GAPDH as a reference gene. The samples were collected from three independent biological replicates.
**CYP450 Activity Analysis.** The CYP3A4 and CYP2C19 ability of the induced cells was measured by using P450-Glo assays (Promega catalogue nos. V9001 and V8881) according to the manufacturer’s protocol. The luminescence was read by an ELISA detector. Results are shown as LCU min⁻¹ normalized to 10⁶ cells.

**Periodic Acid-Schiff Staining.** Periodic acid-Schiff staining (Sigma-Aldrich) was performed according to the manufacturer’s protocol.

**Indocyanine Green Uptake.** Cells were incubated with indocyanine green (ICG, CardioGreen; Sigma-Aldrich, 12633) in DMEM (1 mgmL⁻¹) for 30 min in and 37 °C under 5% CO₂ in a cell incubator. Subsequently, the cells were washed three times with PBS. ICG uptake was visualized using a Nikon TE2000-S microscope.

**Assessment of Liver Function.** Blood serum samples were taken for assessment, and the amount of AST (aspartate transaminase; Roche), ALT (alanine transaminase; Roche), and totalbilirubin (TBIL; Roche) was estimated using commercial kits in accordance with the manufacturer’s protocol.

**HSA ELISA.** The amount of HSA (human serum albumin) in serum was detected using a human-specific ALB ELISA kit (catalogue no. EA3201-1; Assaypro), according to the manufacturer’s instructions.

**Statistical Analysis.** All statistical analyses were performed using the SPSS software package. Statistical significance was defined as P < 0.05. Two-tailed student’s t-test was performed to compare two groups.

**References**

1. Pai, M. et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. *The American journal of gastroenterology*. 103, 1952–1958 (2008).
2. Terai, S. et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. *Stem cells*. 24, 2292–2298 (2006).
3. Vassilopoulos, G., Wang, P. R. & Russell, D. W. Transplanted bone marrow regenerates liver by cell fusion. *Nature*. 422, 901–904 (2003).
4. Peng, L. et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: Short-term and long-term outcomes. *Hepatology*. 54, 820–828 (2011).
5. Apel, A. et al. Suitability of human mesenchymal stem cells for gene therapy depends on the expansion medium. *Experimental Cell Research*. 2009 315, 498–507 (2009).
6. Bajjani, S. et al. Characterization of human adult stem-cell populations isolated from visceral and subcutaneous adipose tissue. *Faseb Journal Official Publication of the Federation of American Societies for Experimental Biology*. 23, 3494–3505 (2009).
7. Dockerty, P. Pancreatic stellate cells can form new β-like cells. *Biochemical journal*. 421, e1–e4 (2009).
8. Karmieli, O., Izhar-Prato, Y., Bulvik, S. & Efrat, S. Generation of Insulin-Producing Cells from Human Bone Marrow Mesenchymal Stem Cells by Genetic Manipulation. *Stem Cells*. 25, 2837–2844 (2007).
9. Yan, Y. et al. Mesenchymal stem cells from human umbilical cords ameliorate mouse hepatic injury in vivo. *Liver International Official. Journal of the International Association for the Study of the Liver*. 29, 356–365 (2009).
10. Addila, S. et al. Clonal identification and characterization of self-renewing pluripotent stem cells in the developing liver. *Journal of Cell Biology*. 156, 173–184 (2002).
11. Okumura, K. et al. Salivary gland progenitor cells induced by duct ligation differentiate into hepatic and pancreatic lineages. *Hepatology*. 38, 104–113 (2003).
12. Suzuki, A., Nakauchi, H. & Taniguchi, H. Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting. *Diabetes*. 53, 2143–2152 (2004).
13. Huch, M. et al. Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver. *Cell*. 160, 299–312 (2015).
14. Huch, M. et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/S-R-spondinaxis. *The EMBO journal*. 32, 2708–2721 (2013).
15. Huch, M. et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. *Nature*. 494, 247–250 (2013).
16. Baek, H. et al. Autonomous isolation, long-term culture and differentiation potential of adult salivary gland-derived stem/progenitor cells. *Journal of Tissue Engineering & Regenerative Medicine*. 8, 717–727 (2014).
17. Dimitriou, I. D. et al. Establishment of a convenient system for the long-term culture and study of non-neoplastic human salivary gland epithelial cells. *European journal of oral sciences*. 110, 21–30 (2002).
18. Nanduri, L. S. Y. et al. Regeneration of irradiated salivary glands with stem cell marker expressing cells. *Radiotherapy & Oncology. Journal of the European Society for Therapeutic Radiology & Oncology*. 99, 367–372 (2011).
19. Chen, M. H. et al. Proliferation and phenotypic preservation of rat parotid acinar cells. *Tissue Engineering*. 11, 526–534 (2005).
20. Kishi, T. et al. Clonal proliferation of multipotent stem/progenitor cells in the neonatal and adult salivary glands. *Biochemical & Biophysical Research Communications*. 340, 544–552 (2006).
21. Visser, K. E. et al. Developmental stage-specific contribution of LGR5+ cells to basal and luminal epithelial lineages in the postnatal mammary gland. *The Journal of pathology*. 228, 300–309 (2012).
22. Hisatomi, Y. et al. Flow cytometric isolation of endodermal progenitors from mouse salivary gland differentiate into hepatic and pancreatic lineages. *Hepatology*. 39, 667–675 (2004).
23. Sato, A. et al. Isolation, tissue localization, and cellular characterization of progenitors derived from adult human salivary glands. *Cloning and stem cells*. 9, 191–205 (2007).
24. Hand, A. R., Pathmanathan, D. & Field, R. B. Morphological features of the minor salivary glands. *Archives of oral biology*. 44, S3–S10 (1999).
25. Du, M. et al. Osteogenic differentiation of human small salivary gland fibroblast-like monoclonal cells. *Chinese Journal of Aesthetic Medicine*. 04, 523–526 (2010).
26. Lu, L. et al. Characterization of a self-renewing and multipotent cell population isolated from human minor salivary glands. *Scientific reports*. 5, 10106 (2015).
27. Maria, O. M. et al. Cell surface markers CD44 and CD166 localized specific populations of salivary acinar cells. *Oral diseases*. 18, 162–168 (2012).
28. Kim, Y. J. et al. Comparative analysis of ABCG2-expressing and label-retaining cells in mouse submandibular gland. *Cell and tissue research*. 334, 47–53 (2008).
29. Klappler, W. et al. Regulation of telomerase activity in quiescent immortalized human cells. *Biochimica Et Biophysica Acta*. 1442, 120–126 (1998).
30. Klug, D. B. et al. Interdependence of cortical thymic epithelial cell differentiation and T-lineage commitment. *Proceedings of the National Academy of Sciences*. 95, 11822–11827 (1998).

31. Popa, I. et al. Regeneration of the adult thymus is preceded by the expansion of K5+ K8+ epithelial cell progenitors and by increased expression of Trp63, cMye and Tcf3 transcription factors in the thymic stroma. *International Immunology*. 19, 1249–1260 (2007).

32. Depreter, M. G. L. et al. Identification of Pten-1 as a specific marker of early thymic epithelial progenitor cells. *Proceedings of the National Academy of Sciences*. 105, 961–966 (2008).

33. Sun, P. et al. Cytokeratin expression during mouse embryonic and early postnatal mammary gland development. *Histochemistry and cell biology*. 133, 213–220 (2010).

34. Lyle, S. et al. The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. *Journal of cell science*. 111, 3179–3188 (1998).

35. Terrace, J. D. et al. Progenitor cell characterization and location in the developing human liver. *Stem cells and development*. 16, 771–778 (2007).

36. Lombaert, I. M. A. et al. Rescue of Salivary Gland Function after Stem Cell Transplantation in Irradiated Glands. *Plos One* 3, e2063 (2008).

37. Park, S. B. et al. SOX2 has a crucial role in the lineage determination and proliferation of mesenchymal stem cells through Dickkopf-1 and c-MYC. *Cell Death & Differentiation*. 19, 534–545 (2012).

38. Arnold, K. et al. Sox2+ adult stem and progenitor cells are important for tissue regeneration and survival of mice. *Cell stem cell*. 9, 317–329 (2011).

39. Snippert, H. J. et al. Lgr6 marks stem cells in the hair follicle that generate all cell lineages of the skin. *Science*. 327, 1385–1389 (2010).

40. Barker, N. et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature*. 449, 1003–1007 (2007).

41. Jaks, V. et al. Lgr5 marks cycling, yet long-lived, hair follicle stem cells. *Nature genetics*. 40, 1291–1299 (2008).

42. Barker, N. et al. Lgr5+ stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. *Cell stem cell*. 6, 25–36 (2010).

43. Shi, F., Kempflle, J. S. & Edge, A. S. B. Wnt-responsive Lgr5-expressing stem cells are hair cell progenitors in the cochlea. *The Journal of Neuroscience*. 32, 9639–9648 (2012).

44. Yee, K. K. et al. Lgr5–EGFP Marks Taste Bud Stem/Progenitor Cells in Posterior Tongue. *Stem Cells*. 31, 992–1000 (2013).

45. Rotter, N. et al. Isolation and characterization of adult stem cells from human salivary glands. *Stem cells and development*. 17, 509–518 (2008).

46. Vroegindeweij, E. et al. Characterization of Lgr5-positive epithelial cells in the murine thymus. *European journal of immunology*. 43, 1243–1251 (2013).

47. Stoller, J. K. & Aboussouan, L. S. A review of α1-antitrypsin deficiency. *American journal of respiratory and critical care medicine*. 185, 246–259 (2012).

48. Weber, L. W. D., Boll, M. & Stampfl, A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. *Critical reviews in toxicology*. 33, 105–136 (2013).

49. Michalopoulos, G. K. Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. *The American journal of pathology*. 176, 2–13 (2010).

50. Martins, P. N. A., Theruvath, T. P. & Neuhaus, P. Rodent models of partial hepatectomies. *Liver International*. 28, 3–11 (2008).

Acknowledgements
We thank Drs. Ran Xiao and Drs. Li Yan for the design of the experiment, Dr. Chun-sheng Han for data analysis and Dr. Yi Zhang for helpful suggestions on manuscript writing.

Author Contributions
Chen Z. wrote the main manuscript text. Chen Z., Zhenmin Z. and Lin L. designed the experiments. Xiaolei J., Ningbei Y., Tao S., Haidong L. and Juan Z. collected the clinical samples. Tinglu H. and Wandi L. performed cell culture. Yan L. and Xiangyu Z. performed the animal procedures. Lei L. and Haizhou T. constructed animal models and in vivo study. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-11880-z.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017